

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 02-414-A1)

In the Application of:)	
)	
John and Maillard)	
)	Examiner: not assigned
Serial No. TBA)	
International Application No. PCT/US03/18517)	
)	
Filed: December 13, 2004)	Art Unit: TBA
International Filing Date: June 11, 2003)	
)	
For: Methods of Treating Alzheimer's Disease Using)	
Aryl Alkanoic Acid Amides)	

INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This prior art statement is filed under 37 C.F.R. §§1.97-1.98 in compliance with the duty of disclosure set forth in 37 C.F.R. §1.56.

In the judgment of the undersigned, the references listed on the attached Form PTO-1449 may be material to the Examiner's consideration of the presently pending claims. However, the references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative relevance between references, whether cited in this statement or prior statements. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. §102.

U.S. Documents

1. U.S. Patent No. 5,559,111 issued September 24, 1996.

Foreign Documents

2. EP 1 2185 201 A2, published June 19, 2002.
3. EP 0 678 514 A1, published April 7, 1995
4. WO 02/02508 A1, published January 10, 2002.
5. WO 01/09083 A1, published February 8, 2001.
6. WO 02/08172 A1, published January 31, 2002.
7. WO 02/100820 A1, published December 19, 2002.

Other Documents

8. Leung Dommienne et al., Journal of Medicinal Chemistry, "Protease Inhibitors: Current Status and Future Prospects" (2000) Vol 43, no. 3 pp.305-341.
9. Mealy, N. E. et al., Drugs of the Future, "Aliskiren fumrate" (2001) Vol. 26, no. 12, pps. 1139-1148.
10. Rahuel J, et al., Chemistry & Biology (2000), Vol.. 7, no. 7, pps. 493-504.
11. S. Roggo, Current Topics in Medicinal Chemistry (2002) Vol. 2, no. 4, pps 359-370.

Also, enclosed is a copy of the European Search Report in which all of the above-listed references were cited during the prosecution of a corresponding PCT application.

In accordance with MPEP Sections 609 and 707.05(b), it is requested the document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or

DT05 Rec'd PCT/PTO 13 DEC 2004

otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

Respectfully submitted,

McDONNELL BOEHNEN
HULBERT & BERGHOFF
300 South Wacker Drive
Chicago, Illinois 60606
(312) 913-0001

Dated: December 13, 2004

By: 

Steven J. Sarussi
Reg. No. 32,784

10/517979

Status Rec'd PCT/PTO \$3 DEC 2004

FORM PTO-1449
(Rev. 2-32)U.S. Department of Commerce
Patent and Trademark OfficeINFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Atty. Docket No.

02-414-A1

Serial No.

TBA

Applicant:

John and Maillard

Filing Date:

December 13, 2004

Group:

TBA

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
1	5,559,111	09/24/1996	Goschke et al.			

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
2	1 215 201 A1	06/19/2002	EP				
3	0 678 514 A1	04/07/1995	EP				
4	WO 02/02508 A1	01/10/2002	PCT				
5	WO 01/09083 A1	02/08/2001	PCT				
6	WO 02/08172 A1	01/31/2002	PCT				
7	WO 02/100820 A1	12/19/2002	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

8	Leung Dommienne et al., Journal of Medicinal Chemistry, "Protease Inhibitors: Current Status and Future Prospects" (2000) Vol 43, no. 3 pp.305-341.
9	Mealy, N. E. et al., Drugs of the Future, "Aliskiren fumrate" (2001) Vol. 26, no. 12, pps. 1139-1148.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

10/517979

D Rec'd PCT/PTO

13 DEC 2004
Sheet 2 of 2FORM PTO-1449
(Rev. 2-32)U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-414-A1

Serial No.

TBA

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant:

John and Maillard

Filing Date:

December 13, 2004

Group:

TBA

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

10	Rahuel J, et al., Chemistry & Biology (2000), Vol.. 7, no. 7, pps. 493-504.
11	S. Roggo, Current Topics in Medicinal Chemistry (2002) Vol. 2, no. 4, pps 359-370.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.